Inhibition of Vascular Endothelial Growth Factor Receptor Signaling in Angiogenic Tumor Vasculature

Advances in Genetics

Volumn 67, Issue C, 2009, Pages 1-27

  Backer, Marina V ^a   Hamby, Carl V ^b   Backer, Joseph M ^a  

^a SIBTECH INC   (United States)

^b NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VASCULOTROPIN A; VASCULOTROPIN RECEPTOR;

ANIMAL; BLOOD VESSEL; DRUG ANTAGONISM; HUMAN; METABOLISM; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); REVIEW; SIGNAL TRANSDUCTION; VASCULARIZATION;

ANIMALS; BLOOD VESSELS; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 71549155919     PISSN: 00652660     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0065-2660(09)67001-2     Document Type: Review

References (105)

1. Al-Jaufy A.Y., Haddad J.E., King S.R., McPhee R.A., and Jackson M.P. Cytotoxicity of a Shiga toxin A subunit-CD4 fusion protein to human immunodeficiency virus-infected cells. Infect. Immun. 62 (1994) 956-960
2. Al-Jaufy A.Y., King S.R., and Jackson M.P. Purification and characterization of a Shiga toxin A subunit-CD4 fusion protein cytotoxic to human immunodeficiency virus-infected cells. Infect. Immun. 63 (1995) 3073-3078
3. Arora N., Maood R., Zheng T., Cai J., Smith L., and Gill P.S. Vascular endothelial growth factor chimeric toxin is highly active against endothelial cells. Cancer Res. 59 (1999) 183-188
4. Backer M.V., and Backer J.M. Functionally active VEGF fusion proteins. Protein Expr. Purif. 23 (2001) 1-7
5. Backer M.V., and Backer J.M. Targeting endothelial cells overexpressing VEGFR-2: Selective toxicity of Shiga-like toxin-VEGF fusion proteins. Bioconj. Chem. 12 (2001) 1066-1073
6. Backer M.V., Budker V.G., and Backer J.M. Shiga-like toxin-VEGF fusion proteins are selectively cytotoxic to endothelial cells overexpressing VEGFR-2. J. Control. Release 74 (2001) 349-355
7. Backer M.V., Gaynutdinov T.I., Gorshkova I.I., Crouch R.J., Hu T., Aloise R., Arab M., Przekop K., and Backer J.M. Humanized docking system for assembly of targeting drug delivery complexes. J. Control. Release 89 (2003) 499-511
8. Backer M.V., Gaynutdinov T.I., Patel V., Bandyopadhyaya A.K., Thirumamagal B.T.S., Tjarks W., Barth R., Claffey K.P., and Backer J.M. Vascular endothelial growth factor selectively targets boronated dendrimers to tumor vasculature. Mol. Cancer Ther. 4 9 (2005) 1423-1429
9. Backer M.V., Levashova Z., Patel V., Jehning B.T., Claffey K., Blankenberg F.G., and Backer J.M. Molecular imaging of VEGF receptors in angiogenic vasculature with single-chain VEGF based probes. Nat. Med. 13 (2007) 504-509
10. Bergers G., and Hanahan D. Modes of resistance to antiangiogenic therapy. Nat. Rev. Cancer 8 (2008) 592-603
11. Bikfalvi A., Sauzeau C., Moukadiri H., Maclouf J., Busso N., Bryckaert M., Plouet J., and Tobelem G. Interaction of vasculotropin/vascular endothelial cell growth factor with human umbilical vein endothelial cells: Binding, internalization, degradation, and biological effects. J. Cell Physiol. 149 (1991) 50-59
12. Blankenberg F.G., Mandl S., Cao Y.-A., et al. Tumor imaging using a standardized radiolabeled adapter protein docked to vascular endothelial growth factor (VEGF). J. Nucl. Med. 45 (2004) 1373-1380
13. Blankenberg F.G., Levashova L., Sarkar S.K., Pizzonia J., Backer M.V., and Backer J.M. Noninvasive assessment of tumor VEGF receptors in response to treatment with pazopanib: A molecular imaging study. Transl. Oncol. 3 1 (2010) in press
14. Bozec A., Gros F.X., Penault-Llorca F., Formento P., Cayre A., Dental C., Etienne-Grimaldi M.C., Fischel J.L., and Milano G. Vertical VEGF targeting: A combination of ligand blockade with receptor tyrosine kinase inhibition. Eur. J. Cancer 44 (2008) 1922-1930
15. Brigotti M., Carnicelli D., Alvergna P., Mazzaracchio R., Sperti S., and Montanaro L. The RNA-N-glycosidase activity of Shiga-like toxin I: Kinetic parameters of the native and activated toxin. Toxiconolgy 35 (1997) 1431-1437
16. Brown L.F., Berse B., Jackman R.W., et al. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Hum. Pathol. 26 (1995) 86-91
17. Cai W., Chen K., Mohamedali K.A., Cao Q., Gambhir S.S., Rosenblum M.G., and Chen X. PET of vascular endothelial growth factor receptor expression. J. Nucl. Med. 47 (2006) 2048-2056
18. Chang Y.S., Adnane J., Trail P.A., Levy J., Henderson A., Xue D., Bortolon E., Ichetovkin M., Chen C., McNabola A., Wilkie D., Carter C.A., et al. Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models. Cancer Chemother. Pharm. 59 (2007) 561-574
19. Chu Q.S. Aflibercept (AVE0005): An alternative strategy for inhibiting tumour angiogenesis by vascular endothelial growth factors. Expert Opin. Biol. Ther. 9 2 (2009) 263-271
20. Claffey K.P., and Robinson G.S. Regulation of VEGF/VPF expression in tumor cells: Consequences for tumor growth and metastasis. Cancer Metastasis Rev. 15 2 (1996) 165-176
21. Cohen K.A., Liu T., Bissonette R., Puri R.K., and Frankel A.E. DAB389EGF fusion protein therapy of refractory glioblastoma multiforme. Curr. Pharm. Biotechnol. 4 (2003) 39-49
22. Couffinhal T., Kearney M., Witzenbichler B., Chen D., Murohara T., Losordo D.W., Symes J., and Isner J.M. Vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) in normal and artherosclerotic human arteries. Am. J. Pathol. 150 (1997) 1673-1685
23. Dempke W.C., and Heinemann V. Resistance to EGF-R (erbB-1) and VEGF-R modulating agents. Eur. J. Cancer 45 7 (2009) 1117-1128
24. Deng Q., and Barbieri J.T. Molecular mechanisms of the cytotoxicity of ADP-ribosylating toxins. Annu. Rev. Microbiol. 62 (2008) 271-288
25. Duttaroy A., Bourbeau D., Wang X.L., and Wang E. Apoptosis rate can be accelerated or decelerated by overexpression or reduction of elongation factor-1α. Exp. Cell Res. 238 1 (1998) 168-176
26. Ebos J.M., Lee C.R., Cruz-Munoz W., Bjarnason G.A., Christensen J.G., and Kerbel R.S. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell. 15 (2009) 232-239
27. Ellis L.M., and Hicklin D.J. VEGF-targeted therapy: Mechanisms of anti-tumour activity. Nat. Rev. Cancer 8 (2008) 579-591
28. Ferrara N. Vascular endothelial growth factor. Arterioscler. Thromb. Vasc. Biol. 29 6 (2009) 789-791
29. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. 1 (1995) 27-31
30. Foss F.M., Saleh M.N., Krueger J.G., Nichols J.C., and Murphy J.R. Diphtheria toxin fusion proteins. In: Frankel A.E. (Ed). Clinical Applications of Immunotoxins (1998), Springer, Berlin, Germany 63-81
31. Frankel A.E., Neville D.M., Bugge T.A., Kreitman R.J., and Leppla S.H. Immunotoxin therapy of hematologic malignancies. Semin. Oncol. 30 (2003) 545-557
32. Gourley M., and Williamson J.S. Angiogenesis: New targets for the development of anticancer chemotherapies. Curr. Pharm. Des. 6 (2000) 417-439
33. Grunwald V., Soltau J., Ivanyi P., Rentschler J., Reuter C., and Drevs J. Molecular targeted therapies for solid tumors: Management of side effects. Onkologie 32 3 (2009) 129-138
34. Gurevich F., and Perazella M.A. Renal effects of anti-angiogenesis therapy: Update for the internist. Am. J. Med. 122 4 (2009) 322-328
35. Hanahan D., and Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86 3 (1996) 353-364
36. Hayden E.C. Cutting off cancer's supply lines. Nature 458 (2009) 686
37. Heckman C.A., Holopainen T., Wirzenius M., Keskitalo S., Jeltsch M., Yla-Herttuala S., Wedge S.R., Jurgensmeier J.M., and Alitalo K. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis. Cancer Res. 68 12 (2008) 4754-4762
38. Holzman C. Whatever happened to immunotoxins? Research, and hope are still alive. J. Natl. Cancer Inst. 101 9 (2009) 624-625
39. Hotz H.G., Hotz B., Bhargava H., and Buhr J. Specific targeting of tumor endothelial cells by a Shiga-like Toxin-VEGF fusion protein as a novel treatment strategy for pancreatic cancer. Deutsche Gesellschaft für Chirurgie Vol. 35 (2006), Springer, Berlin, Heidelberg 5-6
40. Hsu A.R., Cai W., Veeravagu A., Mohamedali K.A., Chen K., Kim S., Vogel H., Hou L.C., Tse V., Rosenblum M.G., and Chen X. Multimodality molecular imaging of glioblastoma growth inhibition with vasculature-targeting fusion toxin VEGF121/rGel. J. Nucl. Med. 48 3 (2007) 445-454
41. Iordanov M.S., and Magun B.E. Different mechanisms of c-Jun NH(2)-terminal kinase-1 (JNK1) activation by ultraviolet-B radiation and by oxidative stressors. J. Biol. Chem. 274 (1999) 25801-25806
42. Iordanov M.S., Pribnow D., Magun J.L., Dinh T.H., Pearson J.A., Chen S.L., and Magun B.E. Ribotoxic stress response: Activation of the stress-activated protein kinase JNK1 by inhibitors of the peptidyl transferase reaction and by sequence-specific RNA. Mol. Cell. Biol. 17 (1997) 3373-3381
43. Izzedine H., Ederhy S., Goldwasser F., Soria J.C., Milano G., Cohen A., Khayat D., and Spano J.P. Management of hypertension in angiogenesis inhibitor-treated patients. Ann. Oncol. 20 5 (2009) 807-815
44. Jackson M.W., Roberts J.S., Heckford S.E., et al. A potential autocrine role for vascular endothelial growth factor in prostate cancer. Cancer Res. 62 (2002) 854-859
45. Jain R.K. Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science 307 (2005) 58-62
46. Jain R.K., Duda D.G., Clark J.W., and Loeffler J.S. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat. Clin. Pract. Oncol. 1 (2006) 24-40
47. Johannsen M., Florcken A., Bex A., Roigas J., Cosentino M., Ficarra V., Kloeters C., Rief M., Rogalla P., Miller K., and Grunwald V. Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis. Eur. Urol. 55 (2009) 1430-1439
48. Jubb A.M., Oates A.J., Holden S., and Koeppen H. Predicting benefit from antiangiogenic agents in malignancy. Nat. Rev. Cancer 6 (2006) 626-635
49. Kaplan B.S., Cleary T.G., and Obrig T.G. Recent advances in understanding the pathogenesis of the hemolytic uremic syndromes. Pediatr. Nephrol. 4 (1990) 276-283
50. Kerbel R.S., and Kamen B.A. The anti-angiogenesis basis of metronomic chemotherapy. Nat. Rev. Cancer 4 (2004) 425-436
51. Koukourakis M.I., Giatromanolaki A., Thorpe P.E., et al. Vascular endothelial growth factor/KDR activated microvessel density versus CD31 standard microvessel density in non-small cell lung cancer. Cancer Res. 60 (2000) 3088-3095
52. Kreitman R.J. Immunotoxins for targeted cancer therapy. AAPS J. 8 3 (2006) E532-E551
53. Kreitman R.J. Recombinant immunotoxins containing truncated bacterial toxins for the treatment of hematologic malignancies. BioDrugs 23 1 (2009) 1-13
54. Kumar R., Knick V.B., Rudolph S.K., Johnson J.H., Crosby R.M., Crouthamel M.-C., Hopper T.M., Miller C.G., Harrington L.E., Onori J.A., Mullin R.J., Gilmer T.M., et al. Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol. Cancer Ther. 6 (2007) 2012-2021
55. Levashova Z., Backer M., Backer J.M., and Blankenberg F.G. Direct labeling of Cys-tag in scVEGF with technetium 99m. Bioconjug. Chem. 19 (2008) 1049-1054
56. Lin M.I., and Sessa W.C. Antiangiogenic therapy: Creating a unique "window" of opportunity. Cancer Cell 6 (2004) 529-531
57. Liu T.F., Cohen K.A., Ramag J.G., Willingham M.C., Thorburn A.M., and Frankel A.E. A diphtheria toxin-epidermel growth factor fusion protein is cytotoxic to human glioblastoma multiforme cells. Cancer Res. 63 8 (2003) 1834-1837
58. Loges S., Mazzone M., Hohensinner P., and Carmeliet P. Silencing or fueling metastasis with VEGF inhibitors: Antiangiogenesis revisited. Cancer Cell 15 (2009) 167-170
59. Lohela M., Bry M., Tammela T., and Alitalo K. VEGFs and receptors involved in angiogenesis versus lymphangiogenesis. Curr. Opin. Cell Biol. 21 2 (2009) 154-165
60. Mancuso M.R., Davis R., Norberg S.M., O'Brien S., Sennino B., Nakahara T., Yao V.J., Inai T., Brooks P., Freimark B., Shalinsky D.R., Hu-Lowe D.D., et al. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J. Clin. Invest. 116 (2006) 2610-2621
61. Manley P.W., Bold G., Bruggen J., et al. Advances in the structural biology, design and clinical development of VEGF-R kinase inhibitors for the treatment of angiogenesis. Biochim. Biophys. Acta 1697 (2004) 17-27
62. Mendel D.B., Laird A.D., Xin X., Louie S.G., Christensen J.G., Li G., Schreck R.E., Abrams T.J., Ngai T.J., Lee L.B., Murray L.J., Carver J., et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationship. Clin. Cancer Res. 9 (2003) 327-337
63. Mohamedali K.A., Poblenz A.T., Sikes C.R., Navone N.M., Thorpe P.E., Darnay B.G., and Rosenblum M.G. Inhibition of prostate tumor growth and bone remodeling by the vascular targeting agent VEGF121/rGel. Cancer Res. 66 22 (2006) 10919-10928
64. Obrig T.G., Del Vecchio P.J., Karmali M.A., Petric M., Moran T.P., and Judge T.K. Pathogenesis of haemolytic uraemic syndrome (Letter). Lancet 2 (1987) 687
65. Obrig T., Louise C.B., Lingwood C.A., Boyd B., Barley-Maloney L., and Daniel T.O. Endothelial heterogeneity in Shiga toxin receptors and responses. J. Biol. Chem. 268 (1993) 15484-15488
66. Olsnes S., Reisbig R., and Eiklid K. Subunit structure of Shigella cytotoxin. J. Biol. Chem. 256 (1981) 8732-8738
67. Olson T.A., Mohanraj D., Roy S., and Ramakrishnan S. Targeting the tumor vasculature: Inhibition of tumor growth by a vascular endothelial growth factor-toxin conjugate. Int. J. Cancer 73 (1997) 865-870
68. Padera T.P., Kuo A.H., Hoshida T., Liao S., Lobo J., Kozak K.R., Fukumura D., and Jain R.K. Differential response of primary tumor versus lymphatic metastasis to VEGFR-2 and VEGFR-3 kinase inhibitors cediranib and vandetanib. Mol. Cancer Ther. 7 8 (2008) 2272-2279
69. Paez-Ribes M., Allen E., Hudock J., Takeda T., Okuyama H., Vinals F., Inoue M., Bergers G., Hanahan D., and Casanovas O. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15 (2009) 220-231
70. Palmowski M., Huppert J., Hauff P., Reinhardt M., Schreiner K., Socher M.A., Hallscheidt P., Kauffmann G.W., Semmler W., and Kiessling F. Vessel fractions in tumor xenografts depicted by flow- or contrast-sensitive three-dimensional high-frequency Doppler ultrasound respond differently to antiangiogenic treatment. Cancer Res. 68 (2008) 7042-7049
71. Pastan I., Hassan R., Fitzgerald D.J., and Kreitman R.J. Immunotoxin therapy of cancer. Nat. Rev. Cancer 6 7 (2006) 559-565
72. Peifer C., Buhler S., Hauser D., Kinkel K., Totzke F., Schachtele C., and Laufer S. Design, synthesis and characterization of N9/N7-substituted 6-aminopurines as VEGF-R and EGF-R inhibitors. Eur. J. Med. Chem. 44 4 (2009) 1788-1793
73. Pennell N.A., and Lynch Jr. T.J. Combined inhibition of the VEGFR and EGFR signaling pathways in the treatment of NSCLC. Oncologist 14 4 (2009) 399-411
74. Potala S., Sahoo S.K., and Verma R.S. Targeted therapy of cancer using diphtheria toxin-derived immunotoxins. Drug Discov. Today 13 17-18 (2008) 807-815
75. Rafii S., Lyden D., Benezra R., Hattori K., and Heissig B. Vascular and haematopoietic stem cells: Novel targets for anti-angiogenesis therapy?. Nat. Rev. Cancer 2 (2002) 826-835
76. Ramakrishnan S., Olson T.A., Bauch V.L., and Mohanraj D. Vascular endothelial growth factor-toxin conjugate specifically inhibits KDR/flk-1 positive endothelial cell proliferation in vitro and angiogenesis in vivo. Cancer Res. 56 (1996) 1324-1330
77. Ran S., Mohamedali K.A., Luster T.A., Thorpe P.E., and Rosenblum M.G. The vascular-ablative agent VEGF(121)/rGel inhibits pulmonary metastases of MDA-MB-231 breast tumors. Neoplasia (New York) 7 5 (2005) 486-496
78. Richardson S.E., Karmali M.A., Becker L.E., and Smith C.R. Hum. Pathol. 19 (1988) 1102-1108
79. Ruan J., Hajjar K., Rafii S., and Leonard J.P. Angiogenesis and antiangiogenic therapy in non-Hodgkin's lymphoma. Ann. Oncol. 20 3 (2009) 413-424
80. Saaristo A., Karpanen T., and Alitalo K. Mechanisms of angiogenesis and their use in the inhibition of tumor growth and metastasis. Oncogene 19 (2000) 6122-6129
81. Sandvig K., Olsnes S., Brown J., Peterson O., and Van Beurs B. J. Cell Biol. 108 (1989) 1331-1343
82. Saxena S.K., O'Brien A.D., and Ackerman E.J. Shiga toxin, Shiga-like toxin II variant, and ricin are all single-site RNA N-glycosidases of 28 S RNA when microinjected into Xenopus oocytes. J. Biol. Chem. 264 (1989) 596-601
83. Schmidt U., Ahmed J., Michalsky E., Hoepfner M., and Preissner R. Comparative VEGF receptor tyrosine kinase modeling for the development of highly specific inhibitors of tumor angiogenesis. Genome Inf. Serv. 20 (2008) 243-251
84. Siemann D.W., Bibby M.C., Dark G.G., Dicker A.P., Eskens F.A., Horsman M.R., Marme D., and Lorusso P.M. Differentiation and definition of vascular-targeted therapies. Clin. Cancer Res. 11 2 Pt 1 (2005) 416-420
85. Sledge Jr. G.W., and Miller K.D. Angiogenesis and antiangiogenic therapy. Curr. Probl. Cancer 26 (2002) 1-60
86. Sloan B., and Scheinfeld N.S. Pazopnib, a VEGF receptor tyrosine kinase inhibitor for cancer therapy. Curr. Opin. Invest. Drugs 9 (2008) 1324-1335
87. Smith N.R., James N.H., Oakley I., Wainwright A., Copley C., Kendrew J., Womersley L.M., Jürgensmeier J.M., Wedge S.R., and Barry S.T. Acute pharmacodynamic and antivascular effects of the vascular endothelial growth factor signaling inhibitor AZD2171 in Calu-6 human lung tumor xenografts. Mol. Cancer Ther. 6 8 (2007) 2198-2208
88. Srivastava S.K., Kumar V., Agarwal S.K., Mukherjee R., and Burman A.C. Synthesis of quinazolines as tyrosine kinase inhibitors. Curr. Med. Chem. AntiCancer Agents 9 3 (2009) 246-275
89. Stirpe F., and Battelli M.G. Ribosome-inactivating proteins: Progress and problems. Cell Mol. Life Sci. 63 16 (2006) 1850-1866
90. Stirpe F., Olsnes S., and Pihl A. Gelonin, a new inhibitor of protein synthesis, nontoxic to intact cells. Isolation, characterization, and preparation of cytotoxic complexes with concanavalin A. J. Biol. Chem. 255 (1980) 6947-6953
91. Talpaz M., Kantarjian H., Freireich E., Lopez V., Zhang W., Cortes-Franco J., Scheinberg D., and Rosenblum M.G. Phase I clinical trial of the anti-CD-33 immunotoxin HuM195/rGel. Am. Assoc. Cancer Res. 44 (2003) 1066
92. Terman B.I., and Dougher-Vermazen M. Biological properties of VEGF/VPF receptors. Cancer Metastasis Rev. 15 2 (1996) 159-163
93. Theodoulou M., Baselga J., Scher H., Dantis L., Trainor K., Mendelsohn J., Howes L., Elledge R., Ravdin P., Bacha P., Brandt-Sarif T., and Osborne K. Phase I dose escalation study of the safety, tolerability, pharmacokinetics and biologic effects of DAB389-EGF in patient with solid malignances that express EGF receptors. Proc. ASCO 14 (1995) 480
94. Thorpe P.E., Chaplin D.J., and Blakey D.C. The first international converence on vascular targeting: Meeting overview. Cancer Res. 63 5 (2003) 1144-1147
95. Vallera D.A., Panoskaltsis-Mortari A., and Blazar B.R. Renal dysfunction accounts for the dose limiting toxicity of DT390anti-CD3sFv, a potential new recombinant anti-GVHD immunotoxin. Protein Eng. 10 (1997) 1071-1076
96. van Cruijsen H., van der Veldt A., and Hoekman K. Tyrosine kinase inhibitors of VEGF receptors: Clinical issues and remaining questions. Front. Biosci. 14 (2009) 2248-2268
97. Veenendaal L.M., Jin H., Ran S., et al. In vitro and in vivo studies of a VEGF121/rGelonin chimeric fusion toxin targeting the neovasculature of solid tumors. Proc. Natl. Acad. Sci. USA 99 (2002) 7866-7871
98. Veikkola T., and Alitalo K. VEGFs, receptors and angiogenesis. Semin. Cancer Biol. 9 3 (1999) 211-220
99. Veikkola T., Karkkainen M., Claesson-Welsh L., and Alitalo K. Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res. 60 (2000) 203-212
100. Wang H., Cai W., Chen K., Li Z.-B., Kashefi A., He L., and Chen X. A new PET tracer specific for vascular endothelial growth factor receptor 2. Eur. J. Nucl. Med. Mol. Imaging 34 (2007) 2001-2010
101. Wang H., Chen K., Niu G., and Chen X. Site-specifically biotinylated VEGF(121) for near-infrared fluorescence imaging of tumor angiogenesis. Mol. Pharm. 6 1 (2009) 285-294
102. Weinstein I.B., and Joe A.K. Mechanisms of disease: Oncogene addiction-A rationale for molecular targeting in cancer therapy. Nat. Clin. Pract. Oncol. 3 (2006) 448-457
103. Weinstein I.B., and Joe A.K. Oncogene addiction. Cancer Res. 68 (2008) 3077-3080
104. Williams J.M., Lea N., Lord J.M., Roberts L.M., Milford D.V., and Taylor C.M. Comparison of ribosome-inactivating proteins in the induction of apoptosis. Toxicol. Lett. 91 2 (1997) 121-127
105. Yang Y., Shuaib A., and Li Q. Quantification of infarct size on focal cerebral ischemia model of rats using a simple and economical method. J. Neurosci. Methods 84 (1998) 9-16